Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients.

Camillo Porta, Ilaria Imarisio, Mara De Amici, Lucia Bonomi, Chiara Paglino, Elisa Biscaldi, Matteo Zimatore, Andrea Sartore-Bianchi, Marco Danova, Remigio Moratti, Alberto Riccardi

Research output: Contribution to journalArticle

Abstract

Using a commercial ELISA assay, we evaluated circulating VEGF and bFGF levels in 203 consecutive patients with solid tumors, and sought a correlation between them and with the grade of anemia. Serum VEGF values were within the normal range in 128 patients (63.05%), with a mean value of 675.04 pg/ml (median, 571.00; range, 0-2796.54). The analysis of VEGF values per tumor group did not provide any statistically significant difference. Regarding bFGF, 143 patients (70.44%) had measurable, and thus abnormal, bFGF values. Overall, mean bFGF serum value was 57.14 pg/ml (median, 8.30; range, 0-4334.71), with the highest bFGF levels found in breast carcinoma patients. As expected, a large number of our patients was fairly anemic, mean hemoglobin level being 11.47 g/dl (median, 11.30; range, 7.1-19.20), the lowest titers being observed in prostate carcinoma patients. No statistically significant correlation was found between serum VEGF and hemoglobin values (r=0.004) but a significant negative correlation was seen between serum bFGF and hemoglobin (r=-0.22, p

Original languageEnglish
Pages (from-to)689-695
Number of pages7
JournalOncology Reports
Volume13
Issue number4
Publication statusPublished - Apr 2005

Fingerprint

Vascular Endothelial Growth Factor A
Anemia
Cytokines
Neoplasms
Hemoglobins
Serum
Prostate
Reference Values
Enzyme-Linked Immunosorbent Assay
Breast Neoplasms
Carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients. / Porta, Camillo; Imarisio, Ilaria; De Amici, Mara; Bonomi, Lucia; Paglino, Chiara; Biscaldi, Elisa; Zimatore, Matteo; Sartore-Bianchi, Andrea; Danova, Marco; Moratti, Remigio; Riccardi, Alberto.

In: Oncology Reports, Vol. 13, No. 4, 04.2005, p. 689-695.

Research output: Contribution to journalArticle

Porta, C, Imarisio, I, De Amici, M, Bonomi, L, Paglino, C, Biscaldi, E, Zimatore, M, Sartore-Bianchi, A, Danova, M, Moratti, R & Riccardi, A 2005, 'Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients.', Oncology Reports, vol. 13, no. 4, pp. 689-695.
Porta, Camillo ; Imarisio, Ilaria ; De Amici, Mara ; Bonomi, Lucia ; Paglino, Chiara ; Biscaldi, Elisa ; Zimatore, Matteo ; Sartore-Bianchi, Andrea ; Danova, Marco ; Moratti, Remigio ; Riccardi, Alberto. / Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients. In: Oncology Reports. 2005 ; Vol. 13, No. 4. pp. 689-695.
@article{4841fa0ea42d4d0f8bf6a127a00d589a,
title = "Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients.",
abstract = "Using a commercial ELISA assay, we evaluated circulating VEGF and bFGF levels in 203 consecutive patients with solid tumors, and sought a correlation between them and with the grade of anemia. Serum VEGF values were within the normal range in 128 patients (63.05{\%}), with a mean value of 675.04 pg/ml (median, 571.00; range, 0-2796.54). The analysis of VEGF values per tumor group did not provide any statistically significant difference. Regarding bFGF, 143 patients (70.44{\%}) had measurable, and thus abnormal, bFGF values. Overall, mean bFGF serum value was 57.14 pg/ml (median, 8.30; range, 0-4334.71), with the highest bFGF levels found in breast carcinoma patients. As expected, a large number of our patients was fairly anemic, mean hemoglobin level being 11.47 g/dl (median, 11.30; range, 7.1-19.20), the lowest titers being observed in prostate carcinoma patients. No statistically significant correlation was found between serum VEGF and hemoglobin values (r=0.004) but a significant negative correlation was seen between serum bFGF and hemoglobin (r=-0.22, p",
author = "Camillo Porta and Ilaria Imarisio and {De Amici}, Mara and Lucia Bonomi and Chiara Paglino and Elisa Biscaldi and Matteo Zimatore and Andrea Sartore-Bianchi and Marco Danova and Remigio Moratti and Alberto Riccardi",
year = "2005",
month = "4",
language = "English",
volume = "13",
pages = "689--695",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients.

AU - Porta, Camillo

AU - Imarisio, Ilaria

AU - De Amici, Mara

AU - Bonomi, Lucia

AU - Paglino, Chiara

AU - Biscaldi, Elisa

AU - Zimatore, Matteo

AU - Sartore-Bianchi, Andrea

AU - Danova, Marco

AU - Moratti, Remigio

AU - Riccardi, Alberto

PY - 2005/4

Y1 - 2005/4

N2 - Using a commercial ELISA assay, we evaluated circulating VEGF and bFGF levels in 203 consecutive patients with solid tumors, and sought a correlation between them and with the grade of anemia. Serum VEGF values were within the normal range in 128 patients (63.05%), with a mean value of 675.04 pg/ml (median, 571.00; range, 0-2796.54). The analysis of VEGF values per tumor group did not provide any statistically significant difference. Regarding bFGF, 143 patients (70.44%) had measurable, and thus abnormal, bFGF values. Overall, mean bFGF serum value was 57.14 pg/ml (median, 8.30; range, 0-4334.71), with the highest bFGF levels found in breast carcinoma patients. As expected, a large number of our patients was fairly anemic, mean hemoglobin level being 11.47 g/dl (median, 11.30; range, 7.1-19.20), the lowest titers being observed in prostate carcinoma patients. No statistically significant correlation was found between serum VEGF and hemoglobin values (r=0.004) but a significant negative correlation was seen between serum bFGF and hemoglobin (r=-0.22, p

AB - Using a commercial ELISA assay, we evaluated circulating VEGF and bFGF levels in 203 consecutive patients with solid tumors, and sought a correlation between them and with the grade of anemia. Serum VEGF values were within the normal range in 128 patients (63.05%), with a mean value of 675.04 pg/ml (median, 571.00; range, 0-2796.54). The analysis of VEGF values per tumor group did not provide any statistically significant difference. Regarding bFGF, 143 patients (70.44%) had measurable, and thus abnormal, bFGF values. Overall, mean bFGF serum value was 57.14 pg/ml (median, 8.30; range, 0-4334.71), with the highest bFGF levels found in breast carcinoma patients. As expected, a large number of our patients was fairly anemic, mean hemoglobin level being 11.47 g/dl (median, 11.30; range, 7.1-19.20), the lowest titers being observed in prostate carcinoma patients. No statistically significant correlation was found between serum VEGF and hemoglobin values (r=0.004) but a significant negative correlation was seen between serum bFGF and hemoglobin (r=-0.22, p

UR - http://www.scopus.com/inward/record.url?scp=23844432066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844432066&partnerID=8YFLogxK

M3 - Article

C2 - 15756443

AN - SCOPUS:23844432066

VL - 13

SP - 689

EP - 695

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -